Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-03-25 | Larosa Joseph J (SVP General Counsel and Secret) | Option Ex | 3,097 | 59.20 | 183,342 |
| 2015-03-25 | Baker Charles A (Director) | Sale | 5,000 | 454.93 | 2,274,660 |
| 2015-03-25 | Baker Charles A (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2015-03-24 | Aberman Michael S (SVP Strategy Investor Relation) | Sale | 4,843 | 478.60 | 2,317,879 |
| 2015-03-18 | Aberman Michael S (SVP Strategy Investor Relation) | Sale | 3,442 | 467.69 | 1,609,802 |
| 2015-03-17 | Aberman Michael S (SVP Strategy Investor Relation) | Option Ex | 11,398 | 24.00 | 273,552 |
| 2015-03-17 | Terifay Robert J (SVP Commercial) | Sale | 10,993 | 451.13 | 4,959,261 |
| 2015-03-16 | Terifay Robert J (SVP Commercial) | Option Ex | 24,375 | 30.63 | 746,606 |
| 2015-03-16 | Larosa Joseph J (SVP General Counsel and Secret) | Sale | 18,311 | 450.00 | 8,239,950 |
| 2015-03-16 | Larosa Joseph J (SVP General Counsel and Secret) | Option Ex | 20,281 | 59.20 | 1,200,635 |
| 2015-02-27 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 3,000 | 416.24 | 1,248,720 |
| 2015-02-24 | Aberman Michael S (SVP Strategy Investor Relation) | Sale | 3,374 | 418.41 | 1,411,701 |
| 2015-02-24 | Terifay Robert J (SVP Commercial) | Sale | 11,173 | 423.67 | 4,733,664 |
| 2015-02-23 | Aberman Michael S (SVP Strategy Investor Relation) | Option Ex | 7,500 | 30.63 | 229,725 |
| 2015-02-23 | Terifay Robert J (SVP Commercial) | Option Ex | 24,375 | 30.63 | 746,606 |
| 2015-02-20 | Goldstein Joseph L (Director) | Sale | 5,000 | 423.88 | 2,119,375 |
| 2015-02-20 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 177.82 | 889,100 |
| 2015-02-20 | Sing George L (Director) | Sale | 15,000 | 423.12 | 6,346,800 |
| 2015-02-20 | Sing George L (Director) | Option Ex | 15,000 | 18.61 | 279,150 |
| 2015-02-20 | Ryan Arthur F (Director) | Sale | 29,250 | 423.03 | 12,373,686 |
| 2015-02-20 | Ryan Arthur F (Director) | Option Ex | 29,250 | 135.50 | 3,963,521 |
| 2015-02-20 | Brown Michael S (Director) | Sale | 1,000 | 422.72 | 422,720 |
| 2015-02-20 | Brown Michael S (Director) | Option Ex | 1,000 | 57.11 | 57,110 |
| 2015-02-17 | Aberman Michael S (SVP Strategy Investor Relation) | Sale | 3,692 | 404.02 | 1,491,641 |
| 2015-02-13 | Aberman Michael S (SVP Strategy Investor Relation) | Option Ex | 7,500 | 24.00 | 180,000 |
| 2015-01-02 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 10,822 | 414.71 | 4,487,948 |
| 2015-01-02 | Schleifer Leonard S (President & CEO) | Sale | 1,500 | 411.75 | 617,625 |
| 2014-12-31 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 25,000 | 52.03 | 1,300,750 |
| 2014-12-24 | Sanofi | Buy | 30,002 | 396.41 | 11,893,032 |
| 2014-12-23 | Sanofi | Buy | 171,457 | 391.47 | 67,119,585 |
| 2014-12-19 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 3,264 | 30.63 | 99,976 |
| 2014-12-18 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 3,264 | 30.63 | 99,976 |
| 2014-12-17 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 2,800 | 30.63 | 85,764 |
| 2014-12-16 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 6,818 | 410.00 | 2,795,380 |
| 2014-12-16 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 6,818 | 41.33 | 281,787 |
| 2014-12-16 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 3,264 | 30.63 | 99,976 |
| 2014-12-16 | Stahl Neil (SVP Research and Development S) | Option Ex | 3,264 | 30.63 | 99,976 |
| 2014-12-16 | Goldberg Murray A (SVP Administration & Asst Secr) | Option Ex | 3,264 | 30.63 | 99,976 |
| 2014-12-15 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 1,668 | 412.65 | 688,305 |
| 2014-12-15 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 1,668 | 30.63 | 51,090 |
| 2014-11-25 | Poon Christine A (Director) | Buy | 400 | 410.00 | 164,000 |
| 2014-11-24 | Stahl Neil (SVP Research and Development S) | Sale | 2,200 | 409.90 | 901,790 |
| 2014-11-24 | Gilman Alfred G (Director) | Sale | 40,000 | 408.44 | 16,337,800 |
| 2014-11-24 | Gilman Alfred G (Director) | Option Ex | 40,000 | 38.31 | 1,532,520 |
| 2014-11-21 | Stahl Neil (SVP Research and Development S) | Sale | 3,107 | 415.16 | 1,289,902 |
| 2014-11-18 | Terifay Robert J (SVP Commercial) | Sale | 22,362 | 404.71 | 9,050,147 |
| 2014-11-18 | Stahl Neil (SVP Research and Development S) | Option Ex | 16,757 | 115.29 | 1,931,914 |
| 2014-11-17 | Terifay Robert J (SVP Commercial) | Option Ex | 48,750 | 21.25 | 1,035,937 |
| 2014-11-13 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 8,575 | 399.58 | 3,426,398 |
| 2014-11-12 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 18,700 | 21.25 | 397,375 |
| 2014-11-12 | Goldstein Joseph L (Director) | Sale | 5,000 | 398.31 | 1,991,550 |
| 2014-11-12 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 177.82 | 889,100 |
| 2014-11-12 | Schleifer Leonard S (President & CEO) | Sale | 42,324 | 400.67 | 16,957,957 |
| 2014-11-11 | Schleifer Leonard S (President & CEO) | Sale | 3,493 | 400.00 | 1,397,200 |
| 2014-10-31 | Schleifer Leonard S (President & CEO) | Sale | 3,453 | 400.11 | 1,381,579 |
| 2014-10-28 | Schleifer Leonard S (President & CEO) | Sale | 69,112 | 405.45 | 28,021,598 |
| 2014-10-27 | Schleifer Leonard S (President & CEO) | Option Ex | 256,808 | 158.01 | 40,578,232 |
| 2014-10-24 | Goldberg Murray A (SVP Administration & Asst Secr) | Sale | 26,788 | 400.06 | 10,716,807 |
| 2014-10-24 | Brown Michael S (Director) | Sale | 5,000 | 399.00 | 1,995,000 |
| 2014-10-24 | Brown Michael S (Director) | Option Ex | 5,000 | 57.11 | 285,550 |
| 2014-10-23 | Goldberg Murray A (SVP Administration & Asst Secr) | Option Ex | 60,000 | 30.63 | 1,837,800 |
| 2014-10-16 | Sanofi | Buy | 122,127 | 334.12 | 40,804,828 |
| 2014-10-15 | Sanofi | Buy | 158,368 | 329.35 | 52,157,867 |
| 2014-09-16 | Sanofi | Buy | 31,717 | 348.94 | 11,067,171 |
| 2014-09-15 | Sanofi | Buy | 80,824 | 343.90 | 27,795,454 |
| 2014-09-12 | Sanofi | Buy | 59,808 | 346.50 | 20,723,172 |
| 2014-09-10 | Vagelos P Roy (Chairman of the Board) | Sale | 10,326 | 350.07 | 3,614,822 |
| 2014-09-08 | Vagelos P Roy (Chairman of the Board) | Sale | 2 | 351.00 | 702 |
| 2014-08-27 | Tessier-lavigne Marc (Director) | Sale | 3,000 | 352.20 | 1,056,600 |
| 2014-08-27 | Tessier-lavigne Marc (Director) | Option Ex | 3,000 | 50.91 | 152,730 |
| 2014-08-27 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 1,681 | 25.94 | 43,605 |
| 2014-08-27 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 5,720 | 314.31 | 1,797,853 |
| 2014-08-27 | Goldstein Joseph L (Director) | Sale | 2,000 | 350.31 | 700,620 |
| 2014-08-26 | Tessier-lavigne Marc (Director) | Option Ex | 1,387 | 50.91 | 70,612 |
| 2014-08-26 | Vagelos P Roy (Chairman of the Board) | Option Ex | 303,909 | 11.64 | 3,537,500 |
| 2014-08-22 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 3,000 | 24.00 | 72,000 |
| 2014-08-19 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 3,611 | 350.00 | 1,263,850 |
| 2014-08-18 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 8,750 | 52.03 | 455,262 |
| 2014-08-18 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 5,875 | 353.00 | 2,073,875 |
| 2014-08-18 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 5,875 | 52.03 | 305,676 |
| 2014-08-15 | Brown Michael S (Director) | Sale | 3,000 | 349.20 | 1,047,600 |
| 2014-08-15 | Brown Michael S (Director) | Option Ex | 3,000 | 33.42 | 100,260 |
| 2014-08-11 | Stahl Neil (SVP Research and Development S) | Sale | 11,646 | 340.21 | 3,962,120 |
| 2014-08-11 | Vagelos P Roy (Chairman of the Board) | Sale | 9,372 | 340.52 | 3,191,353 |
| 2014-08-08 | Stahl Neil (SVP Research and Development S) | Sale | 2,100 | 340.80 | 715,680 |
| 2014-08-08 | Vagelos P Roy (Chairman of the Board) | Sale | 2,600 | 340.33 | 884,858 |
| 2014-08-07 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 6,806 | 338.37 | 2,302,946 |
| 2014-08-07 | Stahl Neil (SVP Research and Development S) | Sale | 741 | 340.71 | 252,466 |
| 2014-08-07 | Vagelos P Roy (Chairman of the Board) | Option Ex | 270,352 | 9.49 | 2,565,640 |
| 2014-08-06 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 15,000 | 21.25 | 318,750 |
| 2014-08-06 | Stahl Neil (SVP Research and Development S) | Option Ex | 35,000 | 21.25 | 743,750 |
| 2014-08-06 | Goldstein Joseph L (Director) | Sale | 2,000 | 331.20 | 662,400 |
| 2014-07-15 | Sanofi | Buy | 129,100 | 315.06 | 40,674,246 |
| 2014-07-14 | Sanofi | Buy | 150,000 | 317.06 | 47,558,250 |
| 2014-07-11 | Sanofi | Buy | 150,000 | 315.10 | 47,264,850 |
| 2014-07-10 | Sanofi | Buy | 175,000 | 310.54 | 54,343,800 |
| 2014-07-09 | Sanofi | Buy | 195,000 | 307.80 | 60,021,000 |
| 2014-07-08 | Sanofi | Buy | 153,000 | 312.20 | 47,766,447 |
| 2014-07-07 | Sanofi | Buy | 256,700 | 313.46 | 80,464,411 |
| 2014-07-03 | Sanofi | Buy | 100,000 | 311.20 | 31,120,000 |
| 2014-07-02 | Sanofi | Buy | 212,400 | 305.58 | 64,905,616 |
| 2014-07-01 | Sanofi | Buy | 212,400 | 295.93 | 62,855,319 |
| 2014-06-30 | Sanofi | Buy | 212,400 | 280.15 | 59,504,921 |
| 2014-06-27 | Sanofi | Buy | 50,000 | 275.22 | 13,760,950 |
| 2014-05-23 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 5,369 | 296.01 | 1,589,304 |
| 2014-05-22 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 11,200 | 21.25 | 238,000 |
| 2014-05-21 | Poon Christine A (Director) | Buy | 255 | 291.90 | 74,434 |
| 2014-05-19 | Sanofi | Buy | 190,751 | 299.45 | 57,119,623 |
| 2014-03-28 | Sanofi | Buy | 306,945 | 307.76 | 94,466,314 |
| 2014-03-27 | Sanofi | Buy | 306,945 | 310.48 | 95,301,511 |
| 2014-03-24 | Baker Charles A (Director) | Sale | 15,000 | 306.77 | 4,601,595 |
| 2014-03-24 | Baker Charles A (Director) | Option Ex | 15,000 | 23.84 | 357,600 |
| 2014-03-24 | Sanofi | Buy | 306,945 | 306.70 | 94,140,031 |
| 2014-03-21 | Sanofi | Buy | 305,115 | 322.74 | 98,471,899 |
| 2014-03-20 | Sanofi | Buy | 57,957 | 327.72 | 18,993,841 |
| 2014-03-19 | Sanofi | Buy | 9,746 | 327.57 | 3,192,497 |
| 2014-03-17 | Brown Michael S (Director) | Sale | 2,000 | 335.05 | 670,096 |
| 2014-03-17 | Brown Michael S (Director) | Option Ex | 2,000 | 33.42 | 66,840 |
| 2014-03-17 | Sanofi | Buy | 60,128 | 328.59 | 19,757,639 |
| 2014-03-14 | Sanofi | Buy | 55,583 | 327.98 | 18,230,223 |
| 2014-03-12 | Sanofi | Buy | 220,995 | 332.33 | 73,444,373 |
| 2014-03-11 | Sanofi | Buy | 180,710 | 332.15 | 60,023,368 |
| 2014-03-10 | Sanofi | Buy | 199,822 | 328.89 | 65,718,658 |
| 2014-03-07 | Sanofi | Buy | 311,691 | 324.81 | 102,734,802 |
| 2014-03-06 | Sanofi | Buy | 80,404 | 339.23 | 27,275,609 |
| 2014-03-03 | Sanofi | Buy | 251,594 | 334.42 | 84,137,310 |
| 2014-02-27 | Brown Michael S (Director) | Sale | 1,000 | 335.00 | 335,000 |
| 2014-02-27 | Vagelos P Roy (Chairman of the Board) | Option Ex | 70,879 | 16.90 | 1,198,067 |
| 2014-02-26 | Brown Michael S (Director) | Option Ex | 1,000 | 57.11 | 57,110 |
| 2014-02-25 | Goldberg Murray A (SVP Administration & Asst Secr) | Sale | 11,871 | 341.22 | 4,050,575 |
| 2014-02-25 | Goldstein Joseph L (Director) | Sale | 1,000 | 338.86 | 338,860 |
| 2014-02-24 | Goldberg Murray A (SVP Administration & Asst Secr) | Option Ex | 30,227 | 77.39 | 2,339,267 |
| 2014-02-21 | Goldberg Murray A (SVP Administration & Asst Secr) | Sale | 21,258 | 334.48 | 7,110,333 |
| 2014-02-21 | Gilman Alfred G (Director) | Sale | 5,000 | 340.00 | 1,700,000 |
| 2014-02-21 | Gilman Alfred G (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2014-02-21 | Sing George L (Director) | Sale | 15,000 | 339.00 | 5,085,000 |
| 2014-02-21 | Sing George L (Director) | Option Ex | 15,000 | 15.80 | 237,000 |
| 2014-02-20 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 3,000 | 21.25 | 63,750 |
| 2014-02-20 | Goldberg Murray A (SVP Administration & Asst Secr) | Option Ex | 50,652 | 61.03 | 3,091,088 |
| 2014-02-20 | Goldstein Joseph L (Director) | Sale | 1,000 | 327.09 | 327,090 |
| 2014-02-18 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 3,648 | 329.79 | 1,203,055 |
| 2014-02-18 | Terifay Robert J (SVP Commercial) | Sale | 12,865 | 332.73 | 4,280,610 |
| 2014-02-14 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 7,500 | 30.63 | 229,725 |
| 2014-02-14 | Terifay Robert J (SVP Commercial) | Option Ex | 27,795 | 21.25 | 590,643 |
| 2014-02-14 | Sing George L (Director) | Sale | 15,000 | 324.00 | 4,860,000 |
| 2014-02-14 | Sing George L (Director) | Option Ex | 15,000 | 9.17 | 137,550 |
| 2014-02-13 | Stahl Neil (SVP Research and Development S) | Sale | 22,612 | 318.98 | 7,212,775 |
| 2014-02-12 | Yancopoulos George (President Regeneron Laboratori) | Sale | 88,987 | 323.02 | 28,744,936 |
| 2014-02-12 | Stahl Neil (SVP Research and Development S) | Option Ex | 54,548 | 18.28 | 997,301 |
| 2014-02-12 | Goldstein Joseph L (Director) | Sale | 1,000 | 320.62 | 320,620 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.